Atara Biotherapeutics (ATRA) KOL Call Suggests Single Arm Trial For Approval - Canaccord
Tweet Send to a Friend
Canaccord Genuity analyst John Newman reiterated a Buy rating and $70.00 price target on Atara Biotherapeutics (NASDAQ: ATRA) after speaking ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
